PMI — Picard Medical Income Statement
0.000.00%
Last trade - 00:00- $19.17m
- $18.28m
- $4.94m
Annual income statement for Picard Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 4.11 | 5.04 | 4.39 | 4.94 |
| Cost of Revenue | ||||
| Gross Profit | -4.99 | -2.7 | -0.112 | -0.204 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 15.2 | 20.5 | 18.1 | 18.2 |
| Operating Profit | -11.1 | -15.5 | -13.7 | -13.3 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -11.2 | -15.6 | -21.1 | -27 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -11.2 | -15.6 | -21.1 | -27 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -11.2 | -15.6 | -21.1 | -27 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -12.7 | -18 | -23.7 | -27 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.175 | -0.249 | -0.329 | -0.366 |